DexCom vs Stryker: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

DexCom Inc (DXCM)

Q3 202622 Jun – 14 Sep 2026

▲3▼1

DexCom gains on FDA clearance, strong Q2, and expanded coverage

FDA clears Stelo for young children The FDA cleared DexCom's Stelo biosensor for children aged 2 and up, opening a new market and supporting the stock.
This is a new regulatory win that expands the addressable market.
Q2 revenue up 13%, guidance raised Q2 revenue rose 13% to $1.31 billion, leading DexCom to raise its 2026 revenue and margin guidance, a sign of strong business momentum.
This is a new financial update that directly boosts investor confidence.
Investor Day and G7 rollout lift shares DexCom's Investor Day sent shares up 25%, and the G7 15 Day rollout progressed, with major PBM coverage now reaching over 7 million non-insulin Type 2 patients.
These are new events that drove the stock higher during the quarter.
Abbott competition intensifies Abbott's FreeStyle Libre topped $2 billion in Q2 sales, and the FDA approved Abbott's Libre Duo, the first U.S. wearable tracking both glucose and ketones, potentially pressuring DexCom's pricing and market share.
This is a new competitive threat that could weigh on DexCom's future growth.

August 20262 Aug – 14 Sep 2026

▲3▼1

DexCom's Strong Q2 and G7 Rollout Drive Gains, but Abbott Competition Looms

Q2 Beat and Raised 2026 Outlook DexCom reported Q2 revenue up 13% to $1.31 billion and raised its full-year revenue and margin guidance, citing manufacturing efficiencies and the G7 15 Day sensor. This directly boosts investor confidence in future profits, pushing the stock up.
This is the core fundamental news that explains the stock's recent strength and improved outlook.
G7 15 Day Rollout and Reimbursement Progress DexCom is on track to convert nearly half of its U.S. customers to the G7 15 Day system by year-end, with coverage from the four largest PBMs covering over 7 million non-insulin Type 2 patients. This expands the market and supports long-term growth.
It shows a concrete driver of future revenue and margin expansion, which is key to the bull case.
Abbott's New Dual Ketone-Glucose Wearable Approved The FDA approved Abbott's Libre Duo 10 Day, the first U.S. wearable to continuously track both glucose and ketones. This could make Abbott's product more attractive and intensify competition, potentially pressuring DexCom's market share and pricing.
It introduces a new competitive threat that could cap DexCom's upside and is a real counterweight to the positive news.
Analyst Upgrades and Fair Value Increase Several analysts raised their price targets to $88–$96, lifting DexCom's fair value estimate to $91.64, after strong Q2 results and margin upside. This reflects growing optimism and can attract more investors, supporting the stock price.
It shows external validation of the company's improved prospects, which influences investor sentiment and demand for the stock.

Latest2 Aug – 14 Sep 2026

▲3▼1

DexCom's Strong Q2 and G7 Rollout Drive Gains, but Abbott Competition Looms

Q2 Beat and Raised 2026 Outlook DexCom reported Q2 revenue up 13% to $1.31 billion and raised its full-year revenue and margin guidance, citing manufacturing efficiencies and the G7 15 Day sensor. This directly boosts investor confidence in future profits, pushing the stock up.
This is the core fundamental news that explains the stock's recent strength and improved outlook.
G7 15 Day Rollout and Reimbursement Progress DexCom is on track to convert nearly half of its U.S. customers to the G7 15 Day system by year-end, with coverage from the four largest PBMs covering over 7 million non-insulin Type 2 patients. This expands the market and supports long-term growth.
It shows a concrete driver of future revenue and margin expansion, which is key to the bull case.
Abbott's New Dual Ketone-Glucose Wearable Approved The FDA approved Abbott's Libre Duo 10 Day, the first U.S. wearable to continuously track both glucose and ketones. This could make Abbott's product more attractive and intensify competition, potentially pressuring DexCom's market share and pricing.
It introduces a new competitive threat that could cap DexCom's upside and is a real counterweight to the positive news.
Analyst Upgrades and Fair Value Increase Several analysts raised their price targets to $88–$96, lifting DexCom's fair value estimate to $91.64, after strong Q2 results and margin upside. This reflects growing optimism and can attract more investors, supporting the stock price.
It shows external validation of the company's improved prospects, which influences investor sentiment and demand for the stock.

July 202622 Jun – 31 Jul 2026

▲3▼1

DexCom's growth story gets FDA boost, raised guidance, but Abbott competition looms

FDA clears Stelo for kids, expanding market DexCom won FDA clearance for its Stelo glucose biosensor in children aged 2 and older who don't use insulin, opening a new patient group. This expands the potential customer base and supports future sales growth, which can lift the stock as investors see a bigger runway.
This is a new regulatory win that directly expands DexCom's addressable market and is a key positive catalyst.
DexCom raises 2026 revenue outlook after strong Q2 DexCom reported Q2 revenue of $1.31 billion, up 13%, and raised full-year 2026 revenue guidance to $5.18–$5.25 billion. It also lifted margin guidance. This shows the business is growing faster than expected, which typically pushes the stock up.
This is a fresh earnings report with raised guidance, a major positive driver for the stock.
Abbott's CGM growth and new sensor intensify competition Abbott's FreeStyle Libre CGM sales topped $2 billion in Q2 and grew 9.5%, and it won CE Mark for a new dual glucose-ketone sensor. Abbott's expansion into the large Type 2 market could pressure DexCom's pricing and market share, a real headwind.
This highlights the main competitive threat that could cap DexCom's upside and is a recurring negative theme.
Investor Day reassures on long-term growth DexCom's management presented robust growth targets through 2030 at its Investor Day, helping drive a 25% share price increase. The event shifted sentiment positively as investors gained confidence in the long-term pipeline and market penetration potential.
This explains a major positive sentiment shift and is a new event that boosted the stock.

22 Jun – 31 Jul 2026

▲3▼1

DexCom's growth story gets FDA boost, raised guidance, but Abbott competition looms

FDA clears Stelo for kids, expanding market DexCom won FDA clearance for its Stelo glucose biosensor in children aged 2 and older who don't use insulin, opening a new patient group. This expands the potential customer base and supports future sales growth, which can lift the stock as investors see a bigger runway.
This is a new regulatory win that directly expands DexCom's addressable market and is a key positive catalyst.
DexCom raises 2026 revenue outlook after strong Q2 DexCom reported Q2 revenue of $1.31 billion, up 13%, and raised full-year 2026 revenue guidance to $5.18–$5.25 billion. It also lifted margin guidance. This shows the business is growing faster than expected, which typically pushes the stock up.
This is a fresh earnings report with raised guidance, a major positive driver for the stock.
Abbott's CGM growth and new sensor intensify competition Abbott's FreeStyle Libre CGM sales topped $2 billion in Q2 and grew 9.5%, and it won CE Mark for a new dual glucose-ketone sensor. Abbott's expansion into the large Type 2 market could pressure DexCom's pricing and market share, a real headwind.
This highlights the main competitive threat that could cap DexCom's upside and is a recurring negative theme.
Investor Day reassures on long-term growth DexCom's management presented robust growth targets through 2030 at its Investor Day, helping drive a 25% share price increase. The event shifted sentiment positively as investors gained confidence in the long-term pipeline and market penetration potential.
This explains a major positive sentiment shift and is a new event that boosted the stock.

Stryker Corporation (SYK)

Q3 202618 Jul – 8 Sep 2026

▲3▼1

Stryker's strong Q2 beat offset by supply snag and joint replacement weakness

Q2 beat and raised guidance Stryker's Q2 sales rose 9.4% to $6.6B and adjusted EPS hit $3.69, beating expectations, prompting management to raise full-year guidance. This shows the core business is healthy and growing faster than expected.
This is the main positive fundamental driver for the period, showing strong financial performance.
Mako robotics milestone and new product launch Mako robotics surpassed 2.5 million procedures, and Stryker launched the Mako RPS handheld knee system. These innovations strengthen Stryker's position in the growing healthcare robotics market and support future demand.
Highlights technological leadership and new product momentum, key for long-term growth.
$100M defense contract and tech partnerships Stryker won a $100M defense contract and advanced acquisitions and Apple Vision Pro technology. This government validation and tech integration open new revenue streams and enhance Stryker's product offerings.
Shows diversification and external validation, which can boost investor confidence.
Manufacturing issue and joint replacement weakness A manufacturing problem limiting inventory and new business is expected to persist into Q4, and joint replacement underperformed on seasonal patterns. These headwinds dragged shares down 7.7% and left SYK down 6.5% YTD.
This is the main negative force that offset strong fundamentals and pressured the stock price.

August 202613 Aug – 8 Sep 2026

▲3▼1

Stryker's strong demand and new tech offset by supply and joint replacement setbacks

Q2 earnings beat with 9% organic growth and raised outlook Stryker reported 9% organic sales growth, adjusted EPS up 17.9% to $3.69, and margin expansion. Management narrowed full-year organic growth outlook to 8.3-9.3%. This shows the core business is healthy and supports a higher stock price.
This is the fundamental earnings result that anchors the period's positive momentum.
$100 million defense contract modification won Stryker's sales unit won a $100 million contract modification from the US Defense Logistics Agency. This adds incremental revenue and validates its products with a key government customer, giving the stock a short-term boost.
A concrete new contract that adds demand and supports the stock.
Mako robotics surpasses 2.5 million procedures; ZuriMED acquisition and Apple Vision Pro app advance Mako robotics hit 2.5 million procedures globally, showing strong adoption. Stryker also agreed to acquire ZuriMED for rotator cuff technology and completed the first hip arthroscopy using its FDA-cleared Apple Vision Pro app. These moves strengthen its long-term competitive position.
Highlights innovation and strategic growth that drive future revenue and market share.
Supply chain and joint replacement woes drag shares down 7.7% At a healthcare conference, executives said a manufacturing problem continues to limit inventory and new business, now expected to persist into Q4. Joint replacement also underperformed on seasonal patterns. This overshadowed recent gains and pressured the stock.
This is the major negative event that caused a sharp sell-off and reflects real operational challenges.

Latest13 Aug – 8 Sep 2026

▲3▼1

Stryker's strong demand and new tech offset by supply and joint replacement setbacks

Q2 earnings beat with 9% organic growth and raised outlook Stryker reported 9% organic sales growth, adjusted EPS up 17.9% to $3.69, and margin expansion. Management narrowed full-year organic growth outlook to 8.3-9.3%. This shows the core business is healthy and supports a higher stock price.
This is the fundamental earnings result that anchors the period's positive momentum.
$100 million defense contract modification won Stryker's sales unit won a $100 million contract modification from the US Defense Logistics Agency. This adds incremental revenue and validates its products with a key government customer, giving the stock a short-term boost.
A concrete new contract that adds demand and supports the stock.
Mako robotics surpasses 2.5 million procedures; ZuriMED acquisition and Apple Vision Pro app advance Mako robotics hit 2.5 million procedures globally, showing strong adoption. Stryker also agreed to acquire ZuriMED for rotator cuff technology and completed the first hip arthroscopy using its FDA-cleared Apple Vision Pro app. These moves strengthen its long-term competitive position.
Highlights innovation and strategic growth that drive future revenue and market share.
Supply chain and joint replacement woes drag shares down 7.7% At a healthcare conference, executives said a manufacturing problem continues to limit inventory and new business, now expected to persist into Q4. Joint replacement also underperformed on seasonal patterns. This overshadowed recent gains and pressured the stock.
This is the major negative event that caused a sharp sell-off and reflects real operational challenges.

July 202618 Jul – 2 Aug 2026

▲3▼1

Stryker's Q2 Beat and Raised Outlook Overshadowed by Post-Earnings Selloff

Q2 Beat and Raised 2026 Guidance Stryker reported Q2 sales of $6.6B (up 9.4%) and adjusted EPS of $3.69, beating estimates, and raised its full-year 2026 outlook. This shows the business is recovering strongly from the cyberattack and supports a higher stock price over time.
This is the core fundamental news that answers why SYK is moving and what drives its value.
Shares Drop 6.4% After Earnings Despite Beat Even though results beat expectations, Stryker shares fell 6.4% after the report, leaving the stock down 6.5% year-to-date and at a 23% discount to one fair-value estimate. This shows investors were disappointed by something beyond the headline numbers, creating near-term price pressure.
This explains the immediate negative price reaction and the current valuation gap, which is central to why the stock is moving now.
Mako RPS Handheld Robotic Knee System Launched in U.S. Stryker launched Mako RPS, a handheld robotic knee replacement system, in the U.S. This extends its robotics franchise into a new form factor, potentially broadening adoption and reinforcing the long-term growth story that supports the stock.
This is a new product catalyst that could drive future demand and investor enthusiasm for SYK.
Rotation into High-Quality Healthcare Names Investor Sarat Sethi highlighted a rotation into cash-flow-generating healthcare companies like Stryker, noting the sector's S&P 500 weighting is at an all-time low. This suggests growing investor demand for SYK shares as money moves out of expensive tech.
This points to a broader market shift that could lift SYK's stock price through increased demand.

18 Jul – 2 Aug 2026

▲3▼1

Stryker's Q2 Beat and Raised Outlook Overshadowed by Post-Earnings Selloff

Q2 Beat and Raised 2026 Guidance Stryker reported Q2 sales of $6.6B (up 9.4%) and adjusted EPS of $3.69, beating estimates, and raised its full-year 2026 outlook. This shows the business is recovering strongly from the cyberattack and supports a higher stock price over time.
This is the core fundamental news that answers why SYK is moving and what drives its value.
Shares Drop 6.4% After Earnings Despite Beat Even though results beat expectations, Stryker shares fell 6.4% after the report, leaving the stock down 6.5% year-to-date and at a 23% discount to one fair-value estimate. This shows investors were disappointed by something beyond the headline numbers, creating near-term price pressure.
This explains the immediate negative price reaction and the current valuation gap, which is central to why the stock is moving now.
Mako RPS Handheld Robotic Knee System Launched in U.S. Stryker launched Mako RPS, a handheld robotic knee replacement system, in the U.S. This extends its robotics franchise into a new form factor, potentially broadening adoption and reinforcing the long-term growth story that supports the stock.
This is a new product catalyst that could drive future demand and investor enthusiasm for SYK.
Rotation into High-Quality Healthcare Names Investor Sarat Sethi highlighted a rotation into cash-flow-generating healthcare companies like Stryker, noting the sector's S&P 500 weighting is at an all-time low. This suggests growing investor demand for SYK shares as money moves out of expensive tech.
This points to a broader market shift that could lift SYK's stock price through increased demand.

Q2 202622 Jun – 8 Jul 2026

▲2▼2

Stryker's Q1 Miss and Cyberattack Hit, but Cash Flow and Robotics Offer Hope

Q1 revenue miss and cyberattack disruption Stryker's Q1 revenue of $6.02B missed the $6.33B consensus, and adjusted EPS of $2.60 fell short of $2.98, largely due to a March 11 cyberattack and $118M restructuring charges. The stock has dropped 17.6% over the past year, reflecting investor concern.
This is the core negative event that explains the recent stock decline and is central to the question.
Analyst price target cuts on softer utilization and inflation BofA cut its price target to $380 from $450, and Leerink lowered its target to $407 from $410, both citing softer healthcare utilization, inflation, and reduced margin expansion. These cuts weigh on sentiment and suggest lower future earnings.
Analyst actions directly influence investor expectations and stock price, and they reflect broader sector headwinds.
Strong free cash flow and reiterated guidance Stryker's free cash flow hit 137% of net income, and management reiterated full-year organic growth of 8-9.5%, expecting to recover most cyberattack-related revenue in H2. This cash strength supports the rebound story and long-term investments.
This positive counterweight shows underlying financial health and management confidence, which could support the stock.
Mako robotics positioned in growing healthcare automation trend Healthcare robotics is projected to grow from $14.9B in 2023 to $57B by 2032, driven by aging populations and clinician shortages. Stryker's Mako orthopedic system exemplifies this trend, potentially boosting demand for its procedures and supporting future growth.
This highlights a long-term growth driver that could offset near-term headwinds and attract investors.

June 202622 Jun – 8 Jul 2026

▲2▼2

Stryker's Q1 Miss and Cyberattack Hit, but Cash Flow and Robotics Offer Hope

Q1 revenue miss and cyberattack disruption Stryker's Q1 revenue of $6.02B missed the $6.33B consensus, and adjusted EPS of $2.60 fell short of $2.98, largely due to a March 11 cyberattack and $118M restructuring charges. The stock has dropped 17.6% over the past year, reflecting investor concern.
This is the core negative event that explains the recent stock decline and is central to the question.
Analyst price target cuts on softer utilization and inflation BofA cut its price target to $380 from $450, and Leerink lowered its target to $407 from $410, both citing softer healthcare utilization, inflation, and reduced margin expansion. These cuts weigh on sentiment and suggest lower future earnings.
Analyst actions directly influence investor expectations and stock price, and they reflect broader sector headwinds.
Strong free cash flow and reiterated guidance Stryker's free cash flow hit 137% of net income, and management reiterated full-year organic growth of 8-9.5%, expecting to recover most cyberattack-related revenue in H2. This cash strength supports the rebound story and long-term investments.
This positive counterweight shows underlying financial health and management confidence, which could support the stock.
Mako robotics positioned in growing healthcare automation trend Healthcare robotics is projected to grow from $14.9B in 2023 to $57B by 2032, driven by aging populations and clinician shortages. Stryker's Mako orthopedic system exemplifies this trend, potentially boosting demand for its procedures and supporting future growth.
This highlights a long-term growth driver that could offset near-term headwinds and attract investors.

22 Jun – 8 Jul 2026

▲2▼2

Stryker's Q1 Miss and Cyberattack Hit, but Cash Flow and Robotics Offer Hope

Q1 revenue miss and cyberattack disruption Stryker's Q1 revenue of $6.02B missed the $6.33B consensus, and adjusted EPS of $2.60 fell short of $2.98, largely due to a March 11 cyberattack and $118M restructuring charges. The stock has dropped 17.6% over the past year, reflecting investor concern.
This is the core negative event that explains the recent stock decline and is central to the question.
Analyst price target cuts on softer utilization and inflation BofA cut its price target to $380 from $450, and Leerink lowered its target to $407 from $410, both citing softer healthcare utilization, inflation, and reduced margin expansion. These cuts weigh on sentiment and suggest lower future earnings.
Analyst actions directly influence investor expectations and stock price, and they reflect broader sector headwinds.
Strong free cash flow and reiterated guidance Stryker's free cash flow hit 137% of net income, and management reiterated full-year organic growth of 8-9.5%, expecting to recover most cyberattack-related revenue in H2. This cash strength supports the rebound story and long-term investments.
This positive counterweight shows underlying financial health and management confidence, which could support the stock.
Mako robotics positioned in growing healthcare automation trend Healthcare robotics is projected to grow from $14.9B in 2023 to $57B by 2032, driven by aging populations and clinician shortages. Stryker's Mako orthopedic system exemplifies this trend, potentially boosting demand for its procedures and supporting future growth.
This highlights a long-term growth driver that could offset near-term headwinds and attract investors.